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Abstract
Background: Adverse drug reactions (ADRs) are associated with increased length of hospital stay, permanent disability
and even death.
Objectives: The purpose of this study was to assess knowledge, attitude, practice (KAP), and barriers related to
Pharmacovigilance (PV) among Pakistani healthcare workers (HCWs).
Methods: A cross-sectional study was conducted in the second largest metropolitan city (Lahore) of Pakistan during a
period of 4 months (JuneeSeptember 2018). A self-administered questionnaire was used to collect data from the doctors,
pharmacists, and nurses from 8 tertiary care hospitals, recruited via convenient sampling. All data were analyzed in
SPSS version 21.
Results: A total of 363 participants (125 doctors, 83 pharmacists and 155 nurses) were recruited. The median [interquartile range (IQR)] knowledge score was 6 (3), with 44.6, 41.9, and 13.5% of participants having poor (score < 6),
moderate (score 6e9), and good (score ≥ 10) PV related knowledge, respectively. Additionally, the median (IQR) attitude
and practice score were 7 (3) and 4 (2), respectively [good attitudes 24.8% (score ≥ 8); good practices 33.9% (score ≥ 5)].
Pharmacist were found to have signiﬁcantly better KAP related to PV than others (p < 0.001). Moreover, male HCWs had
substantially better KAP than females.
Conclusion: Although pharmacist have better KAP scores than other HCWs, yet overall KAP of PV among study
participants were inadequate. Thus, continuous training and teaching programs should be conducted to improve
awareness and to promote ADR reporting.
Keywords: Knowledge, Barriers, Adverse drug reactions, Pakistan, Pharmacovigilance

1. Introduction

A

drug is a peculiar entity having both therapeutics as well as unwanted or adverse
effects. Adverse drug reaction (ADR) is deﬁned as

any response to a drug which is noxious and
unintended that occurs at doses normally used in
patients for prophylaxis, diagnosis, treatment, or
modiﬁcation of physiological function [1]. ADRs
are not only associated with increased length of
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hospital stay and economic burden but may also
lead to serious consequences like congenital
anomaly, permanent disability, life threatening
conditions and death [2,3].
The incidence of emergency hospitalization due to
ADRs ranges 0.2e41.3% globally, among them
28.9% are preventable [4]. In US, 15% of hospital
admissions are due to ADRs. The quality assurance
and medicine safety team of WHO is continuously
promoting safe use of drug [5]. Pharmacovigilance
(PV) is deﬁned as “the science and activities relating
to the detection, assessment, understanding, and
prevention of adverse effects or any other possible
drug-related problems” [6]. Timely identiﬁcation
and management of ADRs can prevent serious
drug-related adverse events. Although medical
professionals are responsible for reporting ADRs,
often times they are not able to do it efﬁciently
either due to lake of time or the inability to identify
and report ADRs which results in under reporting of
ADRs [7,8].
There was no established PV center in Pakistan
until 2011. In 2012, the Supreme Court of Pakistan
issued an order to the government to establish an
independent drug regulatory authority after the
incidence at Punjab Institute of Cardiology that
resulted in more than 200 deaths and hospitalization
of 1000 people that was related to adulteration in
locally manufactured drugs [7]. Thus, Drug Regularity Authority of Pakistan (DRAP) was established
in 2012 to monitor drug related practices in
Pakistan. The country's ﬁrst PV center also established in DRAP where HCWs could report ADRs. In
2018, Government of the Punjab took an excellent
initiative with the development of ‘Pharmacovigilance wing’ for online reporting of ADRs occurring
throughout the health facilities in Province, Punjab.
Since HCWs knowledge, attitudes, and practices
(KAP) related to ADRs are the key predictors for the
efﬁcient working of the PV system. The current
study was carried out to estimate the knowledge,
attitude, practice, and barriers of PV in Lahore, the
capital of province Punjab, Pakistan.

2. Methods
2.1. Participants and study settings
A descriptive cross-sectional study was carried
out among HCWs (medical doctors, nurses, and
pharmacists) in Lahore which is the second largest
metropolitan city of Pakistan. Data were gathered
from 9 public, and 2 private tertiary care hospitals
(Lahore General Hospital, King Edward Medical
University/Mayo Hospital, Punjab Institute of

Cardiology, Services Hospital, Children Hospital,
Shaikh Zaid hospital, Doctors hospital, Shoukat
Khanum Memorial Cancer Hospital, and Mid City
hospital) between JuneeSeptember 2018. A convenient sampling strategy was used to recruit HCWs
providing services in the aforementioned hospitals.
Investigators approached HCWs and briefed them
about the purpose and nature of the study. Those
who were willing to participate were enrolled and
the study questionnaires (hard copies) were
administered.
2.2. Ethical consideration
Ethical approval of the current study was acquired
from the Human Research Ethics Committee of
Punjab University College of Pharmacy, University
of the Punjab, Lahore, Pakistan. A verbal informed
consent was obtained from every volunteer prior to
the administration of study instrument. Moreover,
participants’ were guaranteed of the conﬁdentiality
of their responses.
2.3. Sample size estimation
We calculated the sample size by using the proportional formula of OpenEpi (https://www.
openepi.com/SampleSize/SSPropor.htm)
by
assuming the population size of 100,000 and anticipated frequency of 50%.The maximum required
sample size was 384 HCWs at conﬁdence interval
95%.
2.4. Data collection instrument
A self-administered questionnaire was developed
to measure the knowledge, attitudes, practices, and
barriers of ADR reporting from published literature
[9e15]. The content validation of the questionnaire
were performed by a panel of experts from Punjab
University College of Pharmacy, University of the
Punjab, Lahore, Pakistan. Minor revisions were
recommended by the expert panel in order to
improve clarity and understanding of some of the
questions. After revising the questionnaire in light
of the panel's recommendations, it was pilot tested
among 10 HCWs who reported that all items and
their response options were comprehensible and
relevant to PV/ADRs.
The ﬁnal questionnaire was comprised of ﬁve
sections (Appendix). Section-I had six items to
collect demographic data. Section-II had 12-items
regarding knowledge of PV and 1-item to enquire
the source of information regarding ADRs. Knowledge score was computed by giving one point for
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every right response and zero point for every wrong
response. Knowledge score ranged from 0 to 12;
participants were classiﬁed as having poor, moderate and good knowledge if their score was <6. 6e9
and >9, respectively. Section-III had 10-items to
evaluate the attitude of HCW towards PV. Attitude
score was computed by giving one point for every
right response and zero point for every wrong
response. Attitude score ranged from 0 to 10; participants with scores 8 were considered to have
positive attitude toward pharmacovigilance. Section-IV had 7-items to assess practices-related to
PV. Practice score was computed by giving one
point for every good practice and zero point for
every puny practice. Practice score ranged from 0 to
7; participants with scores 5 were considered to
have better practice-related to pharmacovigilance.
Section-V had 6 questions regarding the barriers of
ADR reporting.
2.5. Statistical analysis
All data were entered and analyzed in SPSS
version 21 for Windows. Continuous and categorical
variables were expressed as median (interquartile
range) and number (percentage), respectively.
ManneWhitney U and KruskaleWallis H tests were
used to assess the signiﬁcant (p < 0.05) difference of
knowledge, attitude, and practices among demographic variables.

3. Results
3.1. Participants’ characteristics
A total of 524 individuals were approached, of
them, 363 gave consent and ﬁlled-out study instruments, with a response rate of 69.3% (125 medical doctors, 83 pharmacists, and 155 nurses).
Demographics of the study sample are shown in
Table 1. The median age of study participants was
28 years, with a preponderance of females (68.9%).

Table 1. Demographic details of participants.
Variables
Age (years)
25
26e30
31e35
36
Gender
Male
Female
Profession
Doctors
Hospital Pharmacists
Nurses
Designations
Doctors
Assistant professor
Registrar
PGR/medial ofﬁcer
House ofﬁcer
Pharmacist
Senior pharmacist
Pharmacist
Nurses
Head nurse
Staff/charge nurse
Work experience (years)
1
>1-3
>3-5
>5-9
10

N (%)
87 (24.0)
141 (38.8)
80 (22.0)
55 (15.2)
113 (31.1)
250 (68.9)
125 (34.4)
83 (22.9)
155 (42.7)

5 (4.0)
5 (4.0)
79 (63.2)
36 (28.8)
18 (21.7)
65 (78.3)
26 (16.5)
129 (83.5)
71 (19.6)
119 (32.8)
45 (12.5)
82 (22.6)
46 (12.7)

poor, moderate, and good ADR knowledge,
respectively. There was a signiﬁcant difference of
ADR knowledge score among study participants
(p < 0.001), with pharmacist having better knowledge scores than doctors as well as nurses (Table 3).
Moreover, male HCWs had signiﬁcantly higher
knowledge scores than females. Majority of the
participants reported that they were getting ADRsrelated information from multiple sources namely
textbooks, medical journals, drug information websites, medical representatives and seminars/
conferences.

3.2. Knowledge of pharmacovigilance

3.3. Attitude of health professionals towards
pharmacovigilance

Reponses to knowledge items regarding ADR are
presented in Table 2. In this study, 57% of the participants’ knew what Pharmacovigilance was and
62.8% knew its purpose. Moreover, 62% chose the
correct deﬁnition of ADRs and 43.8% knew the right
classiﬁcation of ADRs. Interestingly, majority of
Pakistani health professionals did not know where
to report ADRs after identiﬁcation. The median
(IQR) of overall knowledge was 6 (3), with 44.6%,
41.9%, and 13.5% of the study participants having

Participants’ attitude toward PV are shown in
Table 4. Majority of the participants (51%) stated
that ADRs reporting was very time consuming
whereas 54.7% stated that reporting of a just one
ADR would make no substantial contribution to
ADR reporting scheme. Moreover, 54.9% stated that
the identity of HCWs who report ADRs should be
kept conﬁdential. The median (IQR) attitude score
was 7 (3), with 28.4% HCWs having good attitudes
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Table 2. Respondents’ knowledge regarding pharmacovigilance.
Item

N (%)

1. Which of the following correctly deﬁnes Pharmacovigilance?
A. The science and activities of detecting, assessing, understanding and preventing adverse effects or any other drugrelated problems*
B. The science of detecting the type and incidence of adverse drugs reactions (ADRs) after a drug is marketed
C. The process of improving the safety of drugs
D. The science of monitoring ADRs happening in a Hospital
E. Do not know
2. Which of the following correctly describes the purpose of Pharmacovigilance?
A. To enhance patient care and patient safety in relation to use of medicines*
B. To identify predisposing factors of ADRs
C. To identify unknown ADRs
D. To calculate incidence of ADRs
E. Do not know
3. Which of the following accurately deﬁnes an ADR?
A. Any noxious or undesired effect of a drug occurring at normal doses, during normal use*
B. Adverse health outcomes associated with inappropriate drug use
C. Harm resulting from the use of substandard/counterfeit drugs
D. Harm caused by drug overdose
E. Adverse outcomes associated with drug impurity
F. Health problems associated with drug use
G. Do not know
4. What types of ADRs should be reported?
A. All serious ADRs
B. ADRs related to herbal and non-allopathic drugs
C. ADRs to new drugs
D. ADRs to vaccines
E. Unknown ADRs of old drugs
F. All of the above*
5. Which of the following is the extended RawlinseThompson Classiﬁcation of ADRs?
A. Type A, B, C, D, E and F*
B. Type 1, 2, 3, 4, 5, 6 and 7
C. Known, unknown and common, uncommon
D. Reversible and irreversible
E. Do not know
6. Which of the following is major risk factor for ADRs occurrence?
A. Arthritis
B. Renal failure*
C. Visual impairment
D. All of the above
E. Do not know
7. Side effects like headache, fever and vomiting should not be reported.
A. Strongly agree
B. Agree
C. Neutral
D. Disagree*
E. Strongly disagree*
8. Are you aware of any formal reporting system available in other countries?
A. Yes*
B. No
9. Are you aware of any drug that has been banned in the world due to its ADRs?
A. Yes*
B. No
10. Where is the “WHO Collaborating Center for International Drug Monitoring” located?
A. Sweden*
B. Germany
C. United States of America
D. United Kingdom
E. Do not know
11. Which of the following is the WHO online database for reporting ADRs?
A. ADR advisory committee
B. Med safe

207 (57.0)
81
27
32
16

(22.3)
(7.4)
(8.8)
(4.4)

228 (62.8)
44 (12.1)
29 (8.0)
25 (6.9)
37 (10.2)
225 (62.0)
66 (18.2)
26 (7.2)
34 (9.4)
8 (2.2)
4 (1.1)
e
112 (30.9)
21 (5.8)
18 (5.0)
15 (4.1)
20 (5.5)
177 (48.8)
159 (43.8)
25 (6.9)
46 (12.7)
36 (9.9)
97 (26.7)
30 (8.3)
132 (36.4)
16 (4.4)
95 (26.2)
90 (24.8)
60 (16.5)
86 (23.7)
44 (12.1)
114 (31.4)
59 (16.3)
231 (63.6)
132 (36.4)
273 (75.2)
90 (24.8)
114 (31.4)
28 (7.7)
93 (25.6)
36 (9.9)
92 (25.3)
77 (21.2)
42 (11.6)

(continued on next page)
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Table 2. (continued )
Item

N (%)

C. VigiBase*
D. Med watch
E. Do not know
12. Which of the following is the ADR reporting organization in Pakistan?
A. Pakistan Medical and Dental Association
B. Drug Regularity Authority of Pakistan*
C. National Institute of Health
D. No center for reporting
E. Do not know

61 (16.8)
62 (17.1)
121 (33.3)
48 (13.2)
97 (26.7)
81 (22.3)
11 (3.0)
126 (34.7)

*Right answer; ADR-adverse drug reaction; WHO-World Health Organization.

(attitude score  75%). Pharmacists had signiﬁcantly
(P < 0.001) more positive attitudes toward ADRs
reporting than doctors, and nurses (Table 3).
Furthermore, male HCWs had signiﬁcantly better
attitude scores than females (p < 0.001).
3.4. Practices-related to pharmacovigilance
Pakistani HCWs practices-related to PV are
shown in Table 5. A wide majority (81%) of study
participants reported that they have identiﬁed
ADRs; however, approximately 61% of HCWs stated
that they have reported the ADRs. Interestingly,
only 39% of study participants stated that they were
well trained in detection, reporting, and managing

ADRs. Additionally, only 35.5% indicated of
reporting all ADRs, not just serious or life threatening ones. Around 45% of study participants
admitted of not mentioning ADRs on patient records. Median (IQR) of overall ADRs-related practice score was 4 (2), with 33.9% HCWs having good
PV practices. As shown in Table 3, pharmacists
displayed signiﬁcantly better practices-related to
Pharmacovigilance than other HCWs.
3.5. Barriers of pharmacovigilance
Reasons of ADRs under-reporting are shown in
Table 6. Around 53% of study participants agreed
that ADRs under-reporting was due to the belief

Table 3. Comparison of knowledge, attitude and practice scores among demographic variables.
Variables

Sub-categories

25
26e30
31e35
36
P-value
Gender
Male
Female
P-value
Occupation
Medical doctors
Pharmacist
Nurses
P-value
Work experience (years)
1
>1-3
>3-5
>5-9
10
P-value
Post-hoc analysis with Bonferroni correction
Occupation
Medical doctors
Pharmacists
P-value
Medical doctors
Nurses
P-value
Pharmacists
Nurses
P-value
Age

Knowledge score
(Mean rank)

Attitude score
(Mean rank)

Practice score
(Mean rank)

187.07
184.46
179.34
171.53
0.826
223.05
163.44
<0.001
202.24
255.06
126.55
<0.001
186.06
196.37
167.92
160.60
190.49
0.136

196.94
181.55
168.31
176.43
0.333
213.45
167.00
<0.001
198.94
231.57
140.74
<0.001
198.79
184.71
207.27
158.28
163.08
0.031

186.20
190.67
172.81
166.51
0.389
204.14
171.99
0.006
181.14
218.57
163.11
<0.001
177.67
190.63
188.10
163.50
193.38
0.365

90.24
125.98
<0.001
166.18
112.67
<0.001
171.08
91.88
<0.001

95.25
117.07
0.008
175.00
119.05
<0.001
156.51
99.68
<0.001

96.79
116.11
0.021
147.36
134.97
0.196
144.45
106.14
<0.001
(continued on next page)
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Table 3. (continued )
Variables

Sub-categories

Knowledge score
(Mean rank)

Attitude score
(Mean rank)

Practice score
(Mean rank)

Work experience (years)

1
>1-3
P-value
1
>3-5
P-value
1
>5-9
P-value
1
10
P-value
>1-3
>3-5
P-value
>1-3
>5-9
P-value
>1-3
10
P-value
>3-5
>5-9
P-value
>3-5
10
P-value
>5-9
10
P-value

e

99.56
92.32
0.370
56.96
59.62
0.669
85.69
68.65
0.015
63.07
51.54
0.065
80.03
89.02
0.270
106.90
92.44
0.078
85.46
76.63
0.278
75.73
57.56
0.006
51.89
40.24
0.031
64.13
65.16
0.876

e

Table 4. Respondents’ attitudes towards pharmacovigilance.
Statement N (%)

Strongly
Disagree

Disagree

Neutral

Agree

Strongly
Agree

1.
2.
3.
4.
5.
6.
7.
8.

8 (2.2)
12 (3.3)
7 (1.9)
7 (1.9)
30 (8.3)
10 (2.8)
7 (1.9)
28 (7.7)

30 (8.3)
27 (7.4)
26 (7.2)
16 (4.4)
69 (19.0)
43 (11.8)
13 (3.6)
104 (28.7)

19 (5.2)
36 (9.9)
53 (14.6)
34 (9.4)
79 (21.8)
103 (28.4)
21 (5.8)
65 (17.9)

185
137
172
158
122
152
172
122

121 (33.3)
151 (41.6)
105 (28.9)
148 (40.8)
63 (17.4)
55 (15.2)
150 (41.3)
44 (21.1)

18 (5.0)

66 (18.2)

80 (22.0)

140 (38.6)

59 (16.3)

9 (2.5)

28 (7.7)

24 (6.6)

141 (38.8)

161 (44.4)

ADRs should promptly be reported to the Pharmacovigilance center
ADR reporting should be made mandatory
ADR reporting is our professional obligation.
ADR reporting increases patient safety
ADR reporting is time consuming
ADR reporting form is too complex to ﬁll.
Are you willing to implement ADRs reporting in your practice?
I believe that reporting of only one case makes no signiﬁcant
contribution to the ADR reporting scheme.
9. Identity of healthcare worker reporting the ADR must be
kept conﬁdential.
10. Pharmacovigilance should be taught in detail to Healthcare workers.

that all marketed drugs were safe as they have undergone rigorous safety and efﬁcacy trials, 67.3%
stated that it was due to the uncertainty whether the
ADR was due to a particular drug, and 67.7% agreed
that it was because of shortage of time.

4. Discussion
The awareness of ADR and possible barriers in
their reporting were examined in the current study.

(51.0)
(37.7)
(47.4)
(43.5)
(33.6)
(41.9)
(47.4)
(33.6)

Although majority of the study participants were
aware regarding the correct deﬁnition of the pharmacovigilance as well as the purpose of this but
73.3% of the participants were unaware of the
location of PV centers in Pakistan. Similar ﬁndings
have been reported in Kingdom of Saudi Arabia and
India where 60.6%, and 55.5% did not know exact
location of PV centers in their countries [2,15]. In our
study, knowledge of study participants regarding
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Table 5. Practices-related to pharmacovigilance.
Statement N (%)

Disagree

Neutral

Agree

1.
2.
3.
4.

44 (12.1)
95 (26.2)
143 (39.4)
75 (20.6)

25
46
79
66

294
222
141
222

129 (35.5)
68 (18.7)
127 (35.0)

75 (20.7)
94 (25.9)
54 (14.9)

Have you ever identiﬁed an ADR in any patient?
Have you ever reported an ADR?
I have been well trained to detect, report and control ADR.
I am following approaches in preventing ADRs during my
practice/prevented ADRs during my practice.
5. I only report severe or life threatening ADRs.
6. I mention the ADRs on patients' medical record.
7. I have done ADRs reporting at least once in the past 1 year.

(6.9)
(12.7)
(21.8)
(18.2)

(81)
(61.1)
(38.9)
(61.2)

159 (43.8)
201 (55.4)
182 (50.1)

Table 6. Reasons for under reporting of ADRs.
Statement N (%)

Strongly
Disagree

Disagree

Neutral

Agree

Strongly
Agree

1. ADR reporting system is not incorporated because of ﬁnancial issues.
2. ADR reporting system not incorporated because of limited awareness
of the health care professionals.
3. Fatal ADRs are mostly not reported because usually general public
do not allow conducting postmortem studies.
4. ADRs are not reported because of the belief that all marketed drugs
are safe.
5. ADRs are not reported because of uncertainty that ADR occurred due
to drug administered.
6. ADRs are not reported because of shortage of time

20 (5.5)
15 (4.1)

53 (14.8)
26 (7.2)

72 (19.8)
35 (9.6)

137 (37.7)
200 (55.1)

81 (22.3)
87 (24.0)

9 (2.5)

67 (18.5)

48 (13.2)

161 (44.4)

78 (21.5)

15 (4.1)

75 (20.7)

80 (22.0)

110 (30.3)

83 (22.9)

22 (6.1)

40 (11.0)

57 (15.7)

173 (47.7)

71 (19.6)

22 (6.1)

58 (16.0)

37 (10.2)

158 (43.5)

88 (24.2)

the WHO online database for ADR reporting was
very low as only 16.8% participants knew about it.
Furthermore, the location of international center of
ADR monitoring was also poor (31%). By contrast,
Gupta et al. [15] reported that more than 41% HCW
knew about the international ADR monitoring center. Spontaneous reporting by the HCW about the
ADR is the most commonly employed method of
ADR monitoring in Pakistan. Therefore, the
knowledge about the regional ADR monitoring
center is of great value. In the current study, only
26.7% HCWs knew where to report ADR in Pakistan
which was signiﬁcantly higher than the ﬁndings of
Palaian et al. [16] who reported that 41% of Nepali
HCWs knew about the their ADRs reporting center.
After detection of ADRs by the HCWs, it must
immediately be reported to the regional ADRs
monitoring center. In this study, majority (84%) of
the HCWs believed that all ADR should promptly
be reported to the National Pharmacovigilance
Center. These ﬁndings were comparable to the results of Alsaleh and colleagues [14]. It was encouraging to see that majority (88.7%) of our HCWs were
willing to implement PV practice in their health
facilities. Additionally, they also believed that PV
should be taught in detail to all HCWs, and 76.3%
HCWs considered PV activities as professional
obligation which was in contrast to the study conducted among nurses in United Arab Emirates

reporting that around 41% considered PV activities
as professional obligation [8]. Deplorably, 51% of
our study participants considered ADRs reporting
as a very time consuming task which was similar to
ﬁndings of an earlier study [17]. Around 55% of
participants in the present study reported that the
identity of ADR should be kept hidden which was
signiﬁcantly higher to the ﬁndings of a previous
study (18.2%) including Nigerian physicians [18].
All in all, the knowledge, attitude and practices of
PV/ADR were found to be insufﬁcient among our
study population which was comparable to the
ﬁndings of earlier studies from Pakistan [9,10],
Malaysia [11], Turkey [19] and South Africa [20]. We
found out that pharmacists had better knowledge,
attitude and practices scores than doctors and
nurses. This can be due to receiving comprehensive
pharmacology and clinical pharmacy education
during in-school pharmacy education; as PV,
medication errors, drug-related problems, and ADR
detection, reporting and causality assessment are
taught extensively in Doctor of Pharmacy program
in Pakistan. Similar to our ﬁndings, O'Callaghan
et al. also reported that hospital pharmacists had the
most experience and highest mean knowledge
scores related to ADR reporting than other health
professionals [20]. The ﬁndings of Tew et al. also
revealed better awareness of PV and ADR reporting
among pharmacists than doctors [11].
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Surprisingly, a little more than one third of the
study participants believed that reporting of only
one ADR would not make a signiﬁcant contribution
to the overall ADRs reporting scheme. These ﬁndings were in contrast to the study conducted in
south eastern European region [17]. Around 40%
our HCWs stated that they were well trained in
detection, reporting, and prevention of ADR which
was in contrast to a previous study conducted in
Karachi where half of the pharmacist enrolled in the
study were trained in PV activities [10]. More than
half of the HCWs believe that all marketed drugs
were safe and they could not cause severe ADR. In
contrast, Belton reported a very low percentage of
European HCWs who believed all marketed drugs
were completely safe [19].
This study had some limitations. As the study was
conducted in health care institutes of just the Lahore
city, our results and conclusions drawn cannot be
generalized to overall HCWs population of
Pakistan. Another signiﬁcant limitation is the use of
convenience sampling which is known to be associated with over- or under-representation of the
population and selection bias. Additionally, even
though the questions used in the study questionnaire were derived from the previously validated
instruments, we did not perform complete reliability
analysis on the questionnaire and only determined
the face and content validity. We recommend nationally representative studies to determine ADR
reporting practices as well as barriers associated
with ADR reporting.
The results of our study have the following
important implications for future practice.
 Pharmacovigilance should be taught in detail to
all HCWs during in-school education.
 Continuous teaching and training programs
need to be conducted in hospitals to train HCWs
where and how to report ADR in Pakistan
[20,21].
 Educational trainings alone do not necessarily
result in adequate PV practices/ADRs reporting
unless there is a blame-free environment in
hospitals where HCWs are able to report medication errors as well as ADRs without fear of
adverse career-related consequences. Therefore,
the concept of “safety culture” should also be
promoted [14].
 Incentives should be offered to the HCWs for
regular reporting of ADRs [9].
 There is a very high deﬁcit of qualiﬁed and
skilled HCWs in Pakistan [22]. Therefore, health
regulators should take steps necessary to increase the strength of doctors, nurses and

pharmacists in Pakistani healthcare settings [23].
This may help decrease the excessive work-load
and improve patient care as well as ADR
reporting.

5. Conclusions
Overall, Pakistani health professionals have
inadequate information regarding PV. This study
highlights the areas (what, how, and where to report
ADRs in Pakistan) that required improvement in
order to improve patient care by efﬁcient PV.
Therefore, robust and multidimensional approach
(hands-on training, lectures, e-learning modules, PV
workshop, conferences) should be employed to
address them.
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Appendix.
The aim of this study is to estimate healthcare
workers’ knowledge, attitude and practices related
to Pharmacovigilance. This study is strictly for
research purpose and all data given will be treated
with utmost conﬁdentiality.
Please answer the following questions.
Age ___________________________________ years
Gender: A) Male
B) Female
Profession: A) Doctor
B) Pharmacist
C)
Nurse
Designation: _________________________________
Name of hospital: ____________________________
Work experience: _______________________ years
1. Which of the following correctly deﬁnes
Pharmacovigilance?
A. The science and activities of detecting, assessing,
understanding and preventing adverse effects or
any other drug-related problems
B. The science of detecting the type and incidence
of adverse drugs reactions (ADRs) after a drug is
marketed
C. The process of improving the safety of drugs
D. The science of monitoring ADRs happening in a
Hospital
E. Do not know
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2. Which of the following correctly describes the
purpose of Pharmacovigilance?
A. To enhance patient care and patient safety in
relation to use of medicines
B. To identify predisposing factors of ADRs
C. To identify unknown ADRs
D. To calculate incidence of ADRs E. Do not know
3. Which of the following accurately deﬁnes an
ADR?
A. Any noxious or undesired effect of a drug
occurring at normal doses, during normal use
B. Adverse health outcomes associated with inappropriate drug use
C. Harm resulting from the use of substandard/
counterfeit drugs
D. Harm caused by drug overdose
E. Adverse outcomes associated with drug
impurity
F. Health problems associated with drug use
G. Do not know
4. What types of ADRs should be reported?
A.
B.
C.
D.
E.
F.

All serious ADRs
ADRs related to herbal and non-allopathic drugs
ADRs to new drugs
ADRs to vaccines
Unknown ADRs of old drugs
All of the above

5. Which of the following is the extended
RawlinseThompson Classiﬁcation of ADRs?
A.
B.
C.
D.

Type A, B, C, D, E and F
Type 1, 2, 3, 4, 5, 6 and 7
Known, unknown and common, uncommon
Reversible and irreversible E. Do not know

6. Which of the following is major risk factor for
ADRs occurrence?
A.
B.
C.
D.
E.

Arthritis
Renal failure
Visual impairment
All of the above
Do not know

7. Side effects like headache, fever and vomiting
should not be reported.
A.
B.
C.
D.

Strongly agree
Agree
Neutral
Disagree

E. Strongly disagree
8. Are you aware of any formal reporting system
available in other countries?
A. Yes
B. No
9. Are you aware of any drug that has been banned in the world due to its ADRs?
A. Yes
B. No
10. Where the “WHO Collaborating Center for
International Drug Monitoring” is located?
A.
B.
C.
D.
E.

Sweden
Germany
United States of America
United Kingdom
Do not know

11. Which of the following is the WHO online
database for reporting ADRs?
A.
B.
C.
D.
E.

ADR advisory committee
Med safe
VigiBase
Med watch
Do not know

12. Which of the following is the ADR reporting
organization in Pakistan?
A.
B.
C.
D.
E.

Pakistan Medical and Dental Association
Drug Regularity Authority of Pakistan
National Institute of Health
No center for reporting
Do not know

13. Sources of information regarding ADRs to
new drugs?
A.
B.
C.
D.
E.
F.
G.

Textbooks
Journals
Internet
Medical representatives
Seminars/conferences
Direct mail brochures
All of the above

14. ADRs should promptly be reported to the
Pharmacovigilance center
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree
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15. ADR reporting should be made mandatory
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

16. ADR reporting is our professional obligation.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

17. ADR reporting increases patient safety

26. I have been well trained to detect, report and
control ADR.
A) Agree

B) Neutral

C) Disagree

27. I am following approaches in preventing
ADRs during my practice/prevented ADRs during
my practice.
A) Agree

B) Neutral

C) Disagree

28. I only report severe or life threatening ADRs.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

18. ADR reporting is time consuming
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

19. ADR reporting form is too complex to ﬁll.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

20. Are you willing to implement ADRs reporting
in your practice?
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

21. I believe that reporting of only one case makes
no signiﬁcant contribution to the ADR reporting
scheme.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

22. Identity of healthcare worker reporting the
ADR must be kept conﬁdential.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

23. Pharmacovigilance should be taught in detail
to Healthcare workers.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

24. Have you ever identiﬁed an ADR in any
patient?
A) Agree

B) Neutral

C) Disagree

25. Have you ever reported an ADR?
A) Agree

B) Neutral

C) Disagree

A) Agree

B) Neutral

C) Disagree

29. I mention the ADRs on patients' record.
A) Agree

B) Neutral

C) Disagree

30. I have done ADRs reporting at least once in
the past 1 year.
A) Agree

B) Neutral

C) Disagree

31. ADR reporting system is not incorporated
because of ﬁnancial issues.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

32. ADR reporting system not incorporated
because of limited awareness of the health care
professionals.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

33. Fatal ADRs are mostly not reported because
usually general public do not allow conducting
postmortem studies.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

34. ADRs are not reported because of the belief
that all marketed drugs are safe.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

35. ADRs are not reported because of uncertainty
that ADR occurred due to drug administered.
A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

36. ADRs are not reported because of shortage of
time
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A) Strongly agree
tral
D) Disagree

B) Agree
C) NeuE) Strongly disagree

Other reasons for the under-reporting of ADRs:
_______________________________________________
_______________________________________________
_______________________________________________
Thank you for participating in our study.
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